Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/pharmaceutical-biocatalysis/descriptif_4181850
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=4181850

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Pharmaceutical Biocatalysis Fundamentals, Enzyme Inhibitors, and Enzymes in Health and Diseases Jenny Stanford Series on Biocatalysis Series

Langue : Anglais

Coordonnateur : Grunwald Peter

Couverture de l’ouvrage Pharmaceutical Biocatalysis
This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-?designer? approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.

Pharmaceuticals: Some General Aspects Use of Enzymes in the Downstream Processing of Biopharmaceuticals Therapeutic Use of Carbonic Anhydrase Inhibitors and Their Multiple Drug Interactions Fibrinolytic Enzymes for Thrombolytic Therapy Role of Engineered Proteins as Therapeutic Formulations Synthesis of bioactive peptides for pharmaceutical applications Cardiovascular Disease and Oxidative Stress Enzymatic Amino Acid Deprivation Therapies Targeting Cancer Carboxylesterase inhibitors: Relevance for Pharmaceutical Applications Molecular Aspects of the Activity and Inhibition of the FAD-containing Monoamine Oxidases Multifunctional Monoamine Oxidase and Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease The Neurodegenerative Characteristics of Alzheimer’s Disease and Related Multi-Target Drug Design Studies Aldehyde Oxidases as Enzymes in Phase I Drug Metabolism Cytochrome P450 Enzymes for the Synthesis of Novel and Known Drugs and Drug Metabolites Cytochromes P450, Cardiovascular Homeostasis and Disease Protein Degradation Inducers SNIPERs and PROTACs against Oncogenic Proteins Resistance Mechanisms of Tumor Cells Biocatalytic Nanoreactors for Medical Purposes Computer-Aided Drug Design for the Identification of Multi-Target Directed Ligands (MTDLs) in Complex Diseases: An Overview The Development of Improved Therapeutics through a Glycan-‘Designer’ Approach On Biocatalysis as Resourceful Methodology for Complex Syntheses: Selective Catalysis, Cascades, and Biosynthesis

Academic and Professional Practice & Development

Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.